Reata
(Bardoxolone methyl)Phase 3Small molecule
BiogenBardoxolone methyl is used to treat chronic kidney disease, particularly in patients with type 2 diabetes, by helping to protect and improve kidney function.[1] Reata is currently being investigated across 14 indications[3], with its most advanced program in Phase 3.[1]
Reata is one of 379 small molecule programs targeting Mixed Connective Tissue Disease. It is currently in Phase 3.
14
Indications
27
Total Trials
0
Active Trials
378
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 14 indications
Competition
Competitive Landscape
1931 competitors in COVID-19
#DrugCompanyPhaseTrials
1Reata
BiogenPhase 3
Spikevax
ModernaPreclinical
Stivarga
BayerPreclinical
Aimovig
AmgenPreclinical
Singulair
AstraZenecaPreclinical
Angiomax
BBaxter Healthcare Corporation
Preclinical
Rayaldee
OOrganon and Co
Preclinical
Achromycin V
WWyeth-Lederle Vaccines
Preclinical
Calcium
Eli LillyPreclinical
Moderna COVID-19 Vaccine
ModernaPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Chronic Kidney Disease7 trials
Show 4 more trials
Pulmonary Hypertension2 trials
Type 2 Diabetes Mellitus2 trials
Adult2 trials
12 more indications
Alport syndrome1 trial
Pancreatic Cancer1 trial
Patients With Advanced Solid Tumors1 trial
Hepatic Impairment1 trial
Kidney Disease1 trial
COVID-191 trial
Randomized1 trial
Pulmonary Arterial Hypertension1 trial
Absorption1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Bardoxolone methyl. EMBL-EBI & Wellcome Sanger Institute.
- [4]